BioPharmSignal logoBioPharmSignal

Biotech News

Innate Pharma announces conference call and webcast for full year 2025 financial results

Innate Pharma (IPHA)Innate PharmaEarnings

Innate Pharma organise une conférence téléphonique et un webcast pour présenter ses résultats financiers 2025

jeu, 03/19/2026 - 07:00

Press release in English 145.54 Ko Communiqué de presse en français 127.69 Ko

helene

mer, 03/18/2026 - 16:08

Related news

IPHAInnate Pharma2026-07-20 14:53 EST

Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)

SNDXSyndax Pharmaceuticals2026-07-28 11:00 EST

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

REGNRegeneron Pharmaceuticals2026-06-25 20:05 EST

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

BMYBMYBristol-Myers Squibb Company2026-07-30 10:59 EST

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

IPHAInnate Pharma2026-08-14 08:26 EST

Innate Pharma announces conference call and webcast

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

IMCRImmunocore Holdings plc2026-07-30 11:00 EST

Immunocore to report second quarter 2026 financial results and host call on August 6, 2026

EXELExelixis2026-07-22 20:30 EST

Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

View all latest news

Innate Pharma

Innate Immunity Oncology Company Innate Pharma develops antibodies and antibody-drug conjugates that engage innate and adaptive immunity against cancer. Lacutamab Lacutamab targets KIR3DL2 and is being developed for cutaneous T-cell lymphoma. ADC and Partnered Pipeline IPH4502 is a Nectin-4 ADC, while partnered programs include...

Recent company news

IPHAInnate Pharma2026-08-14 08:26 EST

Innate Pharma announces conference call and webcast

IPHAInnate Pharma2026-08-13 07:14 EST

Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares

IPHAInnate Pharma2026-08-10 14:02 EST

Innate Pharma Announces Proposed Offering of Ordinary Shares

IPHAInnate Pharma2026-08-09 21:32 EST

Innate Pharma to advance Lacutamab towards phase 3 following partnership with Sobi and appoints new chief medical officer

IPHAInnate Pharma2026-08-09 20:37 EST

Innate Pharma enters strategic partnership with Sobi to license lacutamab in T-cell lymphoma

Stock data

Close
2.26 USD
Market cap
170.9M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States